<DOC>
	<DOCNO>NCT02544659</DOCNO>
	<brief_summary>This study design evaluate long term efficacy intravenous bisphosphonates bone marrow edema patient SAPHO syndrome .</brief_summary>
	<brief_title>Efficacy Bisphosphonates Patients With Synovitis , Acne , Pustulosis , Hyperostosis , Osteitis ( SAPHO ) Syndrome</brief_title>
	<detailed_description>The study evaluate long term efficacy 3 day , 3 6 month pamidronate disodium administer . Patients administered pamidronate disodium 1 mg/kg , IV , QD , 3 day , every 3 month ( month 6 ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acquired Hyperostosis Syndrome</mesh_term>
	<mesh_term>Pamidronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Male female patient age 18 70 year 2 . Only 1 4 inclusion criterion sufficient arrive diagnosis SAPHO syndromeï¼š Osteoarticular manifestation acne conglobata , acne fulminans , hidradenitis suppurativa Osteoarticular manifestation PPP Hyperostosis ( anterior chest wall , limbs spine ) without dermatosis CRMO involve axial peripheral skeleton without dermatosis Palmoplantar pustulosis ( PPP ) ; chronic recurrent multifocal osteomyelitis ( CRMO ) 3 . MRI show bone marrow edema affect site patient 4 . Blood serum patient show normal white blood cell count , liver renal function 5 . Patients like follow 1 year 6 . Other protocol define inclusion criterion may apply 1 . Women pregnancy lactation . 2 . Septic osteomyelitis 3 . Infectious chest wall arthritis 4 . Infections PPP 5 . Palmoplantar keratodermia 6 . DISH except fortuitous association 7 . Osteoarticular manifestation retinoid therapy 8 . Other protocol define exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Treatment</keyword>
	<keyword>Bisphosphonates</keyword>
	<keyword>Response rate</keyword>
</DOC>